Interprofessional Webinar Series:
Emerging Role of Medical Cannabis for the Seriously Ill
This webinar is presented in collaboration with the
National Hospice and Palliative Care Organization.
Funding Disclosure: No commercial funding has been accepted for the activity.
Date and Time: June 1, 2017, 12:30 PM – 1:30 PM ET (Live)
Location: Online at https://www.mjhspalliativeinstitute.org/e-learning/
Speaker Name and Title:
Bernard Lee, MD
Associate Chief Medical Officer
Purpose: The purpose of this webinar is to provide a basic understanding of the clinical uses of medical marijuana to clinicians.
Participants will be able to:
- Discuss the basic principles of the cannabinoids
- Identify which patients might benefit from a trial of medical marijuana
- Discuss what type of medical marijuana is appropriate for certain medical conditions
Marijuana is now legal for medical use in 28 states and Washington D.C., and is also legal in eight of these states for recreational or ‘adult use.’ Now that medical marijuana is legal in more than half of the U.S., with additional states voting on legislation, it is important for medical professionals to have at least a basic understanding of the risks and benefits of cannabis. Given the volume of anecdotal evidence, plus a small number of randomized controlled trials, it is apparent that there is great potential for cannabis and cannabinoids to provide suffering patients with palliation of many symptoms.
Target Audience: palliative care specialists, pain specialists, primary care providers, nurse practitioners, registered nurses, advanced practice nurses, registered nurses with a specialty in palliative care/hospice, pharmacists, allied health professionals, fellows, residents, and medical students.
Criteria for Successful Completion:
- Attendance at entire session (mandatory for nurses and pharmacists)
- Submission of completed evaluation form (mandatory to receive CE/CME credit for MDs and nurses)
- Submission of completed Verification of Continuing Education Participation Form, Program Evaluation Form, and CE Validation Form (mandatory for pharmacists). Pharmacists must email all three forms to PalliativeInstitute@mjhs.org or fax forms to 212-649-5544 within 45 days of webinar date.
Continuing Education Credits: 1.0
Continuing Education Accreditation:
Physicians: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Hospice and Palliative Care Organization (NHPCO) and MJHS. NHPCO is accredited by the ACCME to provide continuing medical education for physicians.
NHPCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses: NHPCO is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
NHPCO designates this live activity for a maximum of 1.0 contact hour. Nurses should claim only the contact hours commensurate with the extent of their participation in the activity. Accredited status by ANCC refers only to continuing nursing education and does not imply endorsement of any commercial product discussed in conjunction with this activity.
Pharmacists: St. John’s University College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Completion of this program provides a total of 1.0 hours of home-study continuing education credit. In order to obtain credit, participants must complete and submit required continuing education forms. The Universal Activity Number assigned to this program is: #0043-9999-17-068-H01-P. Credit will be posted to CPE Monitor within six weeks.
Individual: $25 (includes CME/CE certificate)
Group: $95 + $5 per CME/CE certificate
Registration fees for webinars are not refundable.
System Requirements for Computers and Mobile Devices:
Bernard Lee, MD, has no disclosures. Any discussion of investigational or unlabeled uses of a product will be identified.
Russell K. Portenoy, MD, Planner, has indicated a relationship with AstraZeneca Pharmaceuticals LP for research support.
No other Planning Committee Member has any disclosures.
Planning Committee Members
Barbara Bouton, MA, FT
Colleen Fleming-Damon, PhDc, APRN-BC, ACHPN-BC, C.T.
Steven R. Gardner, MPA, PAHM
Myra Glajchen, DSW
Jennifer Kennedy, RN, MA, BSN, CHC
Russell K. Portenoy, MD
Karen Richards, PhD, EdS
Judith A. Skretny